<VariationArchive VariationID="1704574" VariationName="NM_015474.4(SAMHD1):c.1436del (p.Glu479fs)" VariationType="Deletion" Accession="VCV001704574" Version="2" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-02-20" DateCreated="2022-09-17" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1699106" VariationID="1704574">
      <GeneList>
        <Gene Symbol="SAMHD1" FullName="SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1" GeneID="25939" HGNC_ID="HGNC:15925" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>20q11.23</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="20" Accession="NC_000020.11" start="36889773" stop="36951708" display_start="36889773" display_stop="36951708" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="20" Accession="NC_000020.10" start="35520226" stop="35580245" display_start="35520226" display_stop="35580245" Strand="-" />
          </Location>
          <OMIM>606754</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_015474.4(SAMHD1):c.1436del (p.Glu479fs)</Name>
      <CanonicalSPDI>NC_000020.11:36904223:T:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>20q11.23</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="20" Accession="NC_000020.11" start="36904224" stop="36904224" display_start="36904224" display_stop="36904224" variantLength="1" positionVCF="36904223" referenceAlleleVCF="CT" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="20" Accession="NC_000020.10" start="35532627" stop="35532627" display_start="35532627" display_stop="35532627" variantLength="1" positionVCF="35532626" referenceAlleleVCF="CT" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>E479fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_281" sequenceAccession="LRG_281">
            <Expression>LRG_281:g.52620del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_281t1" sequenceAccession="LRG_281t1">
            <Expression>LRG_281t1:c.1436del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_281p1" sequenceAccession="LRG_281p1" change="p.Glu479Glyfs">
            <Expression>LRG_281p1:p.Glu479Glyfs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000020.10" sequenceAccession="NC_000020" sequenceVersion="10" change="g.35532627del" Assembly="GRCh37">
            <Expression>NC_000020.10:g.35532627del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000020.11" sequenceAccession="NC_000020" sequenceVersion="11" change="g.36904224del" Assembly="GRCh38">
            <Expression>NC_000020.11:g.36904224del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_017059.1" sequenceAccession="NG_017059" sequenceVersion="1" change="g.52620del">
            <Expression>NG_017059.1:g.52620del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001363729.2" sequenceAccession="NM_001363729" sequenceVersion="2" change="c.1436del">
            <Expression>NM_001363729.2:c.1436del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001350658.1" sequenceAccession="NP_001350658" sequenceVersion="1" change="p.Glu479fs">
            <Expression>NP_001350658.1:p.Glu479fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001363733.2" sequenceAccession="NM_001363733" sequenceVersion="2" change="c.1436del">
            <Expression>NM_001363733.2:c.1436del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001350662.1" sequenceAccession="NP_001350662" sequenceVersion="1" change="p.Glu479fs">
            <Expression>NP_001350662.1:p.Glu479fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_015474.4" sequenceAccession="NM_015474" sequenceVersion="4" change="c.1436del" MANESelect="true">
            <Expression>NM_015474.4:c.1436del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_056289.2" sequenceAccession="NP_056289" sequenceVersion="2" change="p.Glu479fs">
            <Expression>NP_056289.2:p.Glu479fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_015474.4(SAMHD1):c.1436del (p.Glu479fs) AND Aicardi Goutieres syndrome" Accession="RCV002282901" Version="1">
        <ClassifiedConditionList TraitSetID="9630">
          <ClassifiedCondition DB="MedGen" ID="C0393591">Aicardi Goutieres syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-07-12" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_015474.4(SAMHD1):c.1436del (p.Glu479fs) AND Aicardi-Goutieres syndrome 5" Accession="RCV003502616" Version="1">
        <ClassifiedConditionList TraitSetID="1109">
          <ClassifiedCondition DB="MedGen" ID="C2749659">Aicardi-Goutieres syndrome 5</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-12-21" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-12-21" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2022-09-17" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">19525956</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22461318</ID>
        </Citation>
        <DescriptionHistory Dated="2024-02-11">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="9630" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="9456" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Aicardi Goutieres syndrome</ElementValue>
                <XRef ID="230312006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Encephalopathy, familial infantile, with calcification of basal ganglia and chronic cerebrospinal fluid lymphocytosis</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">AGS1</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">AGS</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="575" />
                <XRef ID="575" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Most characteristically, Aicardi-Goutières syndrome (AGS) manifests as an early-onset encephalopathy that usually, but not always, results in severe intellectual and physical disability. A subgroup of infants with AGS present at birth with abnormal neurologic findings, hepatosplenomegaly, elevated liver enzymes, and thrombocytopenia, a picture highly suggestive of congenital infection. Otherwise, most affected infants present at variable times after the first few weeks of life, frequently after a period of apparently normal development. Typically, they demonstrate the subacute onset of a severe encephalopathy characterized by extreme irritability, intermittent sterile pyrexias, loss of skills, and slowing of head growth. Over time, as many as 40% develop chilblain skin lesions on the fingers, toes, and ears. It is becoming apparent that atypical, sometimes milder, cases of AGS exist, and thus the true extent of the phenotype associated with pathogenic variants in the AGS-related genes is not yet known.</Attribute>
                <XRef ID="NBK1475" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301648</ID>
                <ID Source="BookShelf">NBK1475</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/X-ALD-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated lysophosphatidylcholines, X-Linked Adrenoleukodystrophy (X-ALD), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/X-ALD-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, X-ALD: Elevated lysophosphatidylcholines C24:0, C26:0, 2023</CitationText>
              </Citation>
              <XRef ID="51" DB="Orphanet" />
              <XRef ID="C0393591" DB="MedGen" />
              <XRef ID="MONDO:0018866" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS225750" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1109" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6631" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Aicardi-Goutieres syndrome 5</ElementValue>
                <XRef ID="MONDO:0013059" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">AGS5</ElementValue>
                <XRef Type="MIM" ID="612952" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10151" />
                <XRef ID="10151" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Most characteristically, Aicardi-Goutières syndrome (AGS) manifests as an early-onset encephalopathy that usually, but not always, results in severe intellectual and physical disability. A subgroup of infants with AGS present at birth with abnormal neurologic findings, hepatosplenomegaly, elevated liver enzymes, and thrombocytopenia, a picture highly suggestive of congenital infection. Otherwise, most affected infants present at variable times after the first few weeks of life, frequently after a period of apparently normal development. Typically, they demonstrate the subacute onset of a severe encephalopathy characterized by extreme irritability, intermittent sterile pyrexias, loss of skills, and slowing of head growth. Over time, as many as 40% develop chilblain skin lesions on the fingers, toes, and ears. It is becoming apparent that atypical, sometimes milder, cases of AGS exist, and thus the true extent of the phenotype associated with pathogenic variants in the AGS-related genes is not yet known.</Attribute>
                <XRef ID="NBK1475" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301648</ID>
                <ID Source="BookShelf">NBK1475</ID>
              </Citation>
              <XRef ID="51" DB="Orphanet" />
              <XRef ID="C2749659" DB="MedGen" />
              <XRef ID="MONDO:0013059" DB="MONDO" />
              <XRef Type="MIM" ID="612952" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="5026633" SubmissionDate="2022-08-30" DateLastUpdated="2022-09-17" DateCreated="2022-09-17">
        <ClinVarSubmissionID localKey="NM_015474.3:c.1436delA|MedGen:C0393591" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002570883" DateUpdated="2022-09-17" DateCreated="2022-09-17" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-07-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>Variant summary: SAMHD1 c.1436delA (p.Glu479GlyfsX11) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position are associated with Aicardi-Goutires syndrome in HGMD. The variant allele was found at a frequency of 4e-06 in 251464 control chromosomes (gnomAD). To our knowledge, no occurrence of c.1436delA in individuals affected with Aicardi Goutieres Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SAMHD1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_015474.3:c.1436delA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0393591" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11991162</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8029895" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2024-02-14">
        <ClinVarSubmissionID localKey="24853772|MedGen:C2749659" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004343366" DateUpdated="2024-02-14" DateCreated="2024-02-14" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-12-21">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">19525956</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22461318</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Glu479Glyfs*11) in the SAMHD1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SAMHD1 are known to be pathogenic (PMID: 19525956, 22461318). This variant is present in population databases (rs773852483, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with SAMHD1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1704574). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SAMHD1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000020.10:g.35532627del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C2749659" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14200283</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5026633" TraitType="Disease" MappingType="XRef" MappingValue="C0393591" MappingRef="MedGen">
        <MedGen CUI="C0393591" Name="Aicardi Goutieres syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8029895" TraitType="Disease" MappingType="XRef" MappingValue="C2749659" MappingRef="MedGen">
        <MedGen CUI="C2749659" Name="Aicardi-Goutieres syndrome 5" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

